Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 1997

View Archived Issues

Betulinic acid derivatives reported to have anti-HIV activity

Pfizer claims glycogen phosphorylase inhibitors

Piperidine derivatives reported by Schering-Plough

AHP claims smooth muscle cell proliferation inhibitors

Merck & Co. continues to develop farnesyl protein transferase inhibitors

Aminoisoindole derivatives discovered for neuropsychological disorders

A new class of GABA receptor ligands claimed by Neurogen

Novel diabetes treatments reported by Shaman

Hoechst develops antipsychotic agents

Takeda's new cephems

1996 in review: Adcock Ingram

Antineoplastic antibiotics isolated by Japanese investigators

Hepatoprotective activity of Chinese medicine tested in animal models

Progenics awarded grants to develop HIV therapeutics

Demeter receives funding for anticancer program

Pharma Patch restructures

Patent coverage sought for novel approach to reducing side effects of vitamin A

Marnac licenses broad-spectrum antifibrotic drug

Pall Corporation finalizes acquisition

GelMed receives patent coverage for new use of polymers

Golden and Syncor sign letter of intent

Positive results reported from TOBI pivotal trials

Cytogen/Elan oral drug delivery collaboration advances

GeneMedicine IND approved

U.S. patent for Tularik drug discovery assays

Tularik receives patent coverage for protein involved in immune response

ICOS/Glaxo Wellcome collaboration modified

U.S. launch for prostate cancer imaging agent

Gen-Probe diagnostic approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...